Leerink Partners analyst Stephanie Davis maintained a Hold rating on Tabula Rasa HealthCare (NASDAQ:TRHC) on Monday, setting a price target of $49, which is approximately 3.97% above the present share price of $47.13.
Davis expects Tabula Rasa HealthCare to post earnings per share (EPS) of -$1.36 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Hold rating of shares in Tabula Rasa HealthCare, with an average price target of $49.2.
The analysts price targets range from a high of $70 to a low of $40.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $77.05 million and a net profit of -$18.3 million. The company's market cap is $1.17 billion.
According to TipRanks.com, Leerink Partners analyst Stephanie Davis is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 20.7% and a 61.06% success rate.
Tabula Rasa Healthcare, Inc. engages in the development of pharmaceutical software that optimizes medication regimens. It offers cloud-based applications, such as EireneRx and MedWise Advisor. The company was founded by Calvin H. Knowlton and Orsula V. Knowlton in April 2009 and is headquartered in Moorestown, NJ.